Výsledky vyhledávání

Akademický článek

Neoadjuvant Doxorubicin and Docetaxel in Breast Cancer Patients Applied Neutropenic Enterocolitis

Autor: Hatice Aslan Sırakaya, Mevlüde İnanç

Publikováno v: Erciyes Medical Journal, Vol 42, Iss 1, Pp 108-109 (2020)

Neutropenic enterocolitis is an acute complication of neutropenia induced by chemotherapy, characterized by inflammatory processes involving the colon and cecum that can lead to necrosis, hemorrhage, perforation, and septicemia. Usually, this conditi

Externí odkaz: https://doaj.org/article/6aa07c967380497a998bb31753a321c2

Zobrazit plný text záznamu

Latest perspectives on the benefits of neoadjuvant therapy for patients with advanced gastric cancer

Autor: Budija, Tea, Marić-Brozić, Jasmina

Publikováno v: Libri Oncologici : Croatian Journal of Oncology
Volume 51
Issue 1

Treatment for gastric cancer has multiple approaches and options across the world. Standard treatment for the Asian population comprises D2-gastrectomy and adjuvant chemotherapy. However, in Europe and North America, clinical trials have shown that p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______951::38b6ca172bce7eb64fbc195d87a47f45
https://hrcak.srce.hr/file/440495

Zobrazit plný text záznamu

Docetaxel in the treatment of hormone-sensitive prostate cancer : a retrospective analysis of treatment at the Department of Oncology and Radiotherapy University Hospital of Split from 2015 to 2019

Autor: Jozić, Tea

Ciljevi: Primarni cilj diplomskog rada bio je utvrditi postoji li poboljšanje u ukupnom preživljenju (OS) i vremenu do progresije u mCRPC kod bolesnika s primarnim mHSPC liječenih kombiniranom terapijom ADT i docetakselom. Ispitanici i postupci: R

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4112::7b20fbd75e04b16ed2bb55b1aa4429b0
https://repozitorij.svkst.unist.hr/islandora/object/mefst:1677/datastream/PDF

Zobrazit plný text záznamu

Akademický článek

Razvoj novih sistemskih zdravljenj pri bolnikih z razsejanim rakom prostate

Autor: Boštjan Šeruga, Tomaž Milanez, Simona Borštnar, Nataša Snoj Šarvari, Breda Škrbinc

Publikováno v: Onkologija, Vol 15, Iss 2, Pp 106-109 (2011)

Hormonsko zdravljenje s kastracijo je v začetku navadno učinkovito pri večini bolnikov z razsejanim rakom prostate, vendar bolezen čez čas neizbežno napreduje. Docetaksel v kombinaciji s prednizonom predstavlja standardno zdravljenje v prvi lin

Externí odkaz: https://doaj.org/article/aff08e5ddd5f463eb610f57ffbf8792f

Zobrazit plný text záznamu

U kojih bolesnika primijeniti hormonsku terapiju + docetaksel

Autor: Gamulin, Marija, Bebek, Marko, Gnjidic, Milena

Publikováno v: Acta clinica Croatica
Volume 58.
Issue Supplement 2
Acta Clinica Croatica

Docetaxel improved the outcome of patients with mCSPC and became standard of care after CHAARTED , STAMPEDE arm C and GET UG-AFU 15 clinical trials and after subsequent meta-analysis. Patients with high-volume (CHAARTED definition) and high-risk (LAT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::a83196f0eeefd21c582e39f1cfe9f49a
https://hrcak.srce.hr/file/340638

Zobrazit plný text záznamu

Clinical development of new systemic therapies in patients with metastatic prostate cancer

Autor: Šeruga, Boštjan, Milanez, Tomaž, Borštnar, Simona, Snoj Šarvari, Nataša, Škrbinc, Breda

Publikováno v: Onkologija, Vol 15, Iss 2, Pp 106-109 (2011)
Onkologija (Ljubljana)
Onkologija. strokovni časopis za zdravnike, vol. 15, no. 2, pp. 106-109, 2011.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::24dfdb477032319f6d5adaece25710d7
https://revijaonkologija.si/Onkologija/article/view/262

Zobrazit plný text záznamu

[Molecular mechanisms of antitumor activity of taxanes. I. Interaction of docetaxel with microtubules]

Autor: Sabina Tabaczar, Aneta Koceva-Chyła, Karolina Matczak, Krzysztof Gwoździński

Publikováno v: Postępy Higieny i Medycyny Doświadczalnej, Vol 64, Iss 840537, Pp 568-581 (2010)

Docetaxel (Taxotere), a new semisynthetic taxoid, is a mitotic inhibitor, widely used in monotherapy or in combination with other anticancer drugs against many types of cancer. The structure and dynamics of microtubules as the main target for docetax

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::146a0e49cb951ff5adf6bd7dfcd077a9
https://pubmed.ncbi.nlm.nih.gov/21109709

Zobrazit plný text záznamu

Onkološka dilema: da li su docetaxel i paclitaxel klinički različiti

Autor: Herceg, Davorin, Vrbanec, Damir

U zadnjem desetljeću taksani se dokazuju kao vodeći citostatici u liječenju karcinoma dojke....

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::5201994636f22e8431793279518d92ac
https://www.bib.irb.hr/338556

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání